CD274 and metastatic neoplasm: PD-L1+ CTCs were identified in 4%, 5.6%, and 7.4% of patients with early, recurrent, and de novo metastatic disease (p = 0.669) and represented 21.6%, 21.7%, and 10% of total CTCs, respectively.